123 related articles for article (PubMed ID: 18521799)
41. The value of standard serum tumor markers in differentiating mucinous from serous cystic tumors of the pancreas: CEA, Ca 19-9, Ca 125, Ca 15-3.
Bassi C; Salvia R; Gumbs AA; Butturini G; Falconi M; Pederzoli P
Langenbecks Arch Surg; 2002 Nov; 387(7-8):281-5. PubMed ID: 12447553
[TBL] [Abstract][Full Text] [Related]
42. Preoperative differential diagnosis of benign and malignant pancreatic lesions--the value of pancreatic secretory trypsin inhibitor, procarboxypeptidase B, CA19-9 and CEA.
Cerwenka H; Aigner R; Quehenberger F; Werkgartner G; Bacher H; Hauser H; Mischinger HJ
Hepatogastroenterology; 1997; 44(16):1117-21. PubMed ID: 9261609
[TBL] [Abstract][Full Text] [Related]
43. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
44. Serum chemokine CXCL8 as a better biomarker for diagnosis and prediction of pancreatic cancer than its specific receptor CXCR2, C-reactive protein, and classic tumor markers CA 19-9 and CEA.
Litman-Zawadzka A; Łukaszewicz-Zając M; Gryko M; Kulczyńska-Przybik A; Mroczko B
Pol Arch Intern Med; 2018 Sep; 128(9):524-531. PubMed ID: 30057378
[TBL] [Abstract][Full Text] [Related]
45. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
[TBL] [Abstract][Full Text] [Related]
46. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9.
Slesak B; Harlozinska-Szmyrka A; Knast W; Sedlaczek P; van Dalen A; Einarsson R
Cancer; 2000 Jul; 89(1):83-8. PubMed ID: 10897004
[TBL] [Abstract][Full Text] [Related]
47. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer.
Fernández-Fernández L; Tejero E; Tieso A; Rabadán L; Munoz M; Santos I
Int Surg; 1996; 81(4):400-2. PubMed ID: 9127805
[TBL] [Abstract][Full Text] [Related]
48. Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis.
Nishida K; Kaneko T; Yoneda M; Nakagawa S; Ishikawa T; Yamane E; Nishioka B; Miyamoto Y; Takano H; Yoshikawa T; Kondo M
J Surg Oncol; 1999 Jul; 71(3):140-6. PubMed ID: 10404129
[TBL] [Abstract][Full Text] [Related]
49. CA 242 in comparison with established tumour markers in colorectal, pancreatic and lung cancer.
Hasholzner U; Stieber P; Reiter W; Zimmermann A; Hofmann K; Schalhorn A
Anticancer Res; 1999; 19(4A):2477-80. PubMed ID: 10470177
[TBL] [Abstract][Full Text] [Related]
50. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
51. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.
Talar-Wojnarowska R; Gasiorowska A; Olakowski M; Lekstan A; Lampe P; Malecka-Panas E
Pancreatology; 2010; 10(6):689-94. PubMed ID: 21242708
[TBL] [Abstract][Full Text] [Related]
52. Cytokeratin serum biomarkers in patients with colorectal cancer.
Holdenrieder S; Stieber P; Liska V; Treska V; Topolcan O; Dreslerova J; Matejka VM; Finek J; Holubec L
Anticancer Res; 2012 May; 32(5):1971-6. PubMed ID: 22593474
[TBL] [Abstract][Full Text] [Related]
53. [Urine diacetylspermine as a novel tumor marker for pancreatobiliary carcinomas].
Yamaguchi K; Nagano M; Torada N; Hamasaki N; Kawakita M; Tanaka M
Rinsho Byori; 2004 Apr; 52(4):336-9. PubMed ID: 15164602
[TBL] [Abstract][Full Text] [Related]
54. Novel serum tumor marker, RCAS1, in pancreatic diseases.
Yamaguchi K; Enjoji M; Nakashima M; Nakamuta M; Watanabe T; Tanaka M
World J Gastroenterol; 2005 Sep; 11(33):5199-202. PubMed ID: 16127752
[TBL] [Abstract][Full Text] [Related]
55. Utility of endoscopic ultrasound, cytology and fluid carcinoembryonic antigen and CA 19-9 levels in pancreatic cystic lesions.
Aljebreen AM; Romagnuolo J; Perini R; Sutherland F
World J Gastroenterol; 2007 Aug; 13(29):3962-6. PubMed ID: 17663510
[TBL] [Abstract][Full Text] [Related]
56. Pancreatic cancer and tumor markers: role of the newly identified CAR-3 antigen.
Giulianotti PC; Boggi U; Ferdeghini M; Di Candio G; Caravaglios G; Bellini R; Mosca F
Ann Ital Chir; 1997; 68(3):307-13. PubMed ID: 9419908
[TBL] [Abstract][Full Text] [Related]
57. Toward standardized high-throughput serum diagnostics: multiplex-protein array identifies IL-8 and VEGF as serum markers for colon cancer.
Bünger S; Haug U; Kelly FM; Klempt-Giessing K; Cartwright A; Posorski N; Dibbelt L; Fitzgerald SP; Bruch HP; Roblick UJ; von Eggeling F; Brenner H; Habermann JK;
J Biomol Screen; 2011 Oct; 16(9):1018-26. PubMed ID: 21807963
[TBL] [Abstract][Full Text] [Related]
58. Urine diacetylspermine as a novel tumour maker for pancreatobiliary carcinomas.
Yamaguchi K; Nakamura M; Shirahane K; Konomi H; Torata N; Hamasaki N; Kawakita M; Tanaka M
Dig Liver Dis; 2005 Mar; 37(3):190-4. PubMed ID: 15888284
[TBL] [Abstract][Full Text] [Related]
59. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
Ng WW; Tong KJ; Tam TN; Lee SD
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
[TBL] [Abstract][Full Text] [Related]
60. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma.
Dima SO; Tanase C; Albulescu R; Herlea V; Chivu-Economescu M; Purnichescu-Purtan R; Dumitrascu T; Duda DG; Popescu I
Pancreas; 2012 Oct; 41(7):1001-7. PubMed ID: 22722257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
